Stratifying Patients for Treatment Eligibility

EP: 1.Alzheimer Disease: Clinical Burden and Treatment

EP: 2.Unmet Needs in Treatment of Alzheimer Disease

EP: 3.Patient Journey to Health Care System and Diagnosis

EP: 4.Increased Prevalence of Alzheimer Disease

EP: 5.Health Inequities Among Patient Populations With AD

EP: 6.Key Drivers for Health Care Utilization and Spending

EP: 7.Diagnostic Process for Individuals With Suspected AD

EP: 8.Goals of AD Therapy With Early Detection

EP: 9.Improved Tracking of AD Comorbidities and Progression

EP: 10.Improving Access to Appropriate AD Care

EP: 11.Developing Policies for Early Biomarker Detection

Now Viewing

EP: 12.Stratifying Patients for Treatment Eligibility

EP: 13.Offsetting the Increased Cost of AD Treatment

EP: 14.The American Brain Foundation: Driving AD Treatment Development

EP: 15.Disease-Modifying Therapy: Defining Response

EP: 16.The Promising Future of Alzheimer Disease Treatment

Neil Minkoff, MD: One of the things that is good about focusing the health care system on a problem is the potential exposure to a new therapy, particularly a newer, more expensive therapy. Look at how much of a difference we started paying to, first rheumatoid arthritis, then psoriasis, then psoriatic arthritis, or the changes in the way we approach MS [multiple sclerosis]. The health care system needed to understand who gets medicine, who does not get medicine, and what we do about it. As we are now staring into a world where the problem is increasing due to the aging of the population, and we have potential DMTs [disease-modifying therapies] coming along, how do we start, a) figuring out who is going to get them, and b) making sure that is an appropriate conversation? How would you start to think about what a threshold for therapy would be? I will ask Richard to kick that off because I am assuming that some of the work you have done has been thinking about how we identify the right patient.

Richard Isaacson, MD: We keep it simple. If a person has a family member or a family history of Alzheimers disease by self-report and no or minimal cognitive complaints, then that is the right patient for us. That is how we stratify patients. We have a memory arm of the clinic that treats people with dementia, and we have a preventive arm that treats people in the pre-dementia phase. We are trying to keep it simple. When we think of early detection and we think of digital devices, we think of online testing.

We think of all the different options out there. For example, before people even come into our clinic [Weill Cornell Medicine], they have to go online and fill out a 45-minute questionnaire that goes into our research database. It has a ton of information there. We also have them take some online cognitive tests before they even come into the clinic. They do some education about what prevention is, and what is and what is not in our control. We are careful about the word prevention. We have to promise not to overpromise, we are honest and up front. We can only do the best we can, and we are going to do everything we can, but in no way, shape, or form is this perfect.

The moral of the story is that we screen patients carefully. Before they come sit next to me, we have an hour-and-a-half of to-dos beforehand. The goal is to see people who are affected, who probably have some degree of genetic risk, who are concerned about their brain health, and who are proactive, want to do something, and have no or minimal cognitive complaints.

Transcript edited for clarity.